AGP Picks
View all

Maryland Tech Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Tech Journal.

Press releases published on November 5, 2026

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
MacroGenics to Participate in Upcoming Investor Conferences
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
Synaptics Reports First Quarter Fiscal 2027 Results
CarGurus Announces Third Quarter 2026 Results
Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
EverCommerce Announces Third Quarter 2026 Financial Results
RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
Equillium to Participate in Upcoming Investor Conferences
Inspired Reports Third Quarter 2026 Results
Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis
Castellum Announces Third Quarter 2026 Financial Results
Aeluma to Participate in 2026 Stifel Deep Tech Summit
Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
IBEX Reports Record Start to Fiscal 2027, Raises Full Year Guidance
SoundHound AI Reports Record Q3 Revenue and Guides to Sustained Adjusted EBITDA Profitability within 2H 2027

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Maryland Tech Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.